Evaluating biomarkers' effects on immune response after stem cell transplants
Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells: MENTALO Study
NA · Centre Hospitalier Universitaire de Saint Etienne · NCT04517656
This study is testing how certain markers in the blood can help us understand the immune response in adults receiving stem cell transplants for blood cancers.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne (other) |
| Drugs / interventions | cyclophosphamide, Chemotherapy |
| Locations | 1 site (Saint-Etienne) |
| Trial ID | NCT04517656 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the expression of various biomarkers during allogeneic hematopoietic stem cell transplantation to understand their impact on post-transplant immune responses. By analyzing blood samples from adult patients with malignant hemopathy, the research seeks to establish correlations between biomarker profiles and patient outcomes. The ultimate goal is to develop predictive tools for post-transplant responses and to determine the appropriateness of targeted therapies for individual patients. This study will be conducted as part of the standard care process without altering the treatment regimen.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with malignant hemopathy who are indicated for allogeneic hematopoietic stem cell transplantation.
Not a fit: Patients receiving transplants from cord blood or haplo-identical donors, or those undergoing specific conditioning treatments, may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved prediction of post-transplant outcomes and more personalized treatment strategies for patients undergoing stem cell transplants.
How similar studies have performed: While the exploration of biomarkers in this context is relatively novel, similar studies have shown promise in understanding immune responses in other transplant settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient, over 18 years of age, suffering from a malignant hemopathy (without exception), * Patient for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated, * Signed informed consent, * Patient covered by a social security scheme. Exclusion Criteria: * Allogeneic hematopoietic stem cell transplantation from cord blood or haplo-identical transplant, * Allogeneic transplant with post-transplant cyclophosphamide treatment, * Allograft with sequential conditioning.
Where this trial is running
Saint-Etienne
- CHU de Saint-Etienne — Saint-Etienne, France (RECRUITING)
Study contacts
- Principal investigator: Jérôme Cornillon, MD — CHU de Saint-Etienne
- Study coordinator: Jérôme Cornillon, MD
- Email: elisabeth.daguenet@chu-st-etienne.fr
- Phone: 477917089
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Malignant Hemopathy, Allograft, Hematopoietic stem cells, Biomarkers, Immune response